The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
Open Access
- 11 April 2022
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (3) , e12680
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Impact of apixaban on routine and specific coagulation assays: a practical laboratory guideThrombosis and Haemostasis, 2013
- Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literatureThrombosis Research, 2012
- Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in HumansDrug Metabolism and Disposition, 2012
- Impact of dabigatran on a large panel of routine or specific coagulation assaysThrombosis and Haemostasis, 2012
- Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacementThrombosis Research, 2011
- Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration timeThrombosis and Haemostasis, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009